# NRC earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/NRC) · [Earnings tab](https://www.lopjlb.com/stock/NRC?tab=earnings)

Updated: 2026-10-26T02:26:20

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of earnings calls NRC moved from a period of modest revenue decline driven by the Canadian location closure and legacy solution discontinuation (2022 Q3‑Q4) toward a flatter top line with incremental growth in new sales tied to the Human Understanding Program (2023 Q2‑Q4). Operating income remained pressured early on due to higher marketing, talent and automation spend, but sequential margin improvements emerged in late 2023 as the sales force expanded and workforce reductions took effect. The Human Understanding Program consistently gained traction, expanding from four adopters in 2022 Q3 to 91 systems by 2023 Q3 with contract‑value growth. Capital allocation stayed stable, with recurring innovation spend, dividends and buybacks, while the pipeline surpassed $100 million in 2023 Q4. Management introduced AI‑driven solutions and reorganized technology teams in 2024 Q1, signaling a strategic shift toward automation. Persistent fears around revenue concentration, talent retention and margin pressure recurred throughout, while new concerns about competition, regulation and AI implementation surfaced in 2024. Overall, the narrative reflects a transition from short‑term revenue headwinds to longer‑term growth levers centered on program adoption, sales force scaling and AI‑enabled efficiency.

## Latest CallCard · Q4

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q4:** —
- **2024 Q1:** NRC reported flat Q1 revenue, outlined aggressive AI-driven growth plans, added leadership, and reaffirmed its financial outlook while noting modest net-debt increase.
- **2023 Q4:** NRC reports flat revenue but expanding margins, $100M+ pipeline, new exec hires, and aggressive capital returns; 2024 starts flat with higher expenses pressuring margins until pipeline converts later in year.
- **2023 Q3:** NRC reports slight revenue growth, TRCV $144.3M, operating income down 10% YoY but margin up 8.3% QoQ; sales force up 19%, headcount down 11%, Human Understanding Program adoption at 91 systems with 13% contract value growth.
- **2023 Q2:** NRC Q2 2023: Revenue down 3% YoY, but new sales up 53% driven by human understanding program rollout; TRCV $146.6M; margins improved sequentially; capital allocation maintained.
- **2023 Q1:** NRC Health Q1 2023 revenue down 5% YoY due to Canadian closure; core TRCV up 1%; operating income down 23% on higher marketing spend; capital allocation maintained with $2.9M innovation, $3M dividends, $2M buybacks; no analyst questions.
- **2022 Q4:** NRC Health Q4 revenue slightly down due to Canadian closure; core offerings grew 7% driven by price increases and upsells; operating income fell 5-7% on inflation and talent investments; TRCV $146.8M; capital allocation prioritizes innovation, dividends, buybacks, and HQ renovation.
- **2022 Q3:** NRC Q3 2022: TRCV down 2% YoY to $148M; core TRCV up 2%; human understanding program adds 4 clients (2 new, 2 upsell); investing in sales, marketing, automation; net income down 15% YoY.

## Theme arcs

- **Revenue Trend** (deteriorating): Revenue declined YoY in 2022‑2023 due to Canadian closure and legacy loss; later flattened with modest new‑sale growth.
- **Margin Trend** (improving): Operating margin compressed early but showed sequential QoQ improvement from Q3 2023 onward as cost alignment and workforce reductions took effect.
- **Human Understanding Program Adoption** (improving): Adoption grew from 4 clients in 2022 Q3 to 91 systems and 13% contract‑value growth by 2023 Q3, driving new‑sale acceleration.
- **Sales Force Expansion** (improving): Expansion progressed from back‑filling in 2022 Q3 to a 19% increase in Q3 2023 and >20% growth since mid‑2022, supporting pipeline conversion.
- **Capital Allocation Consistency** (stable): Innovation spend, dividends and buybacks remained steady each quarter.
- **Pipeline Growth** (improving): Pipeline exceeded $100 M in Q4 2023, with recurring new‑sale growth of 18% YoY in Q4 2023.
- **AI‑Driven Growth Plans** (new): 2024 Q1 introduced AI‑enhanced solutions and product domain reorganization as a future growth engine.
- **Talent Retention Concerns** (deteriorating): Higher associate turnover and increased talent spend were highlighted repeatedly.
- **Cost Structure Pressure** (deteriorating): Inflationary and marketing cost pressures recurred, affecting operating income.
- **Competitive Landscape** (new): 2024 Q1 noted intensified competition from new entrants and health‑system rivals.

## Guidance path

2022 Q3:vague → 2022 Q4:vague → 2023 Q1:vague → 2023 Q2:vague → 2023 Q3:vague → 2023 Q4:vague → 2024 Q1:maintained → 2025 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/NRC`